Treatment of infections caused by susceptible strains of microorganisms, especially gram-negative bacteria.
Adults, Children, and Infants: IV/IM 15 mg/kg (ideal body weight)/day in 2 or 3 divided doses. Treatment in heavier patients should not exceed 1.5 g/day.
Uncomplicated utis: IV/IM 250 mg twice daily.
Newborns: IV/IM Loading dose of 10 mg/kg is recommended followed by 7.5 mg/kg q 12 h. Lower doses may be needed in first 2 wk of life.
Inhibits production of bacterial protein, causing bacterial cell death.
Generally not indicated for long-term therapy because of ototoxicity and nephrotoxicity.
Use Cautiously in:
EENT: ototoxicity (vestibular and cochlear) .
GU: nephrotoxicity .
Neuro: enhanced neuromuscular blockade.
Misc: hypersensitivity reactions.
Therapeutic Classification: anti-infectives
Pharmacologic Classification: aminoglycosides
Absorption: Poorly absorbed from the GI tract. Well absorbed after IM administration; IV administration results in complete bioavailability.
Distribution: Widely distributed throughout extracellular fluid. Crosses the placenta; small amounts enter breast milk. Poor penetration into CSF (increased when meninges inflamed).
Metabolism/Excretion: Excretion is mainly (>90%) renal; minimal amounts are metabolized by the liver.
Half-life: Infants >7 days: 4–5 hr; Children: 1.6–2.5 hr; Adolescents: 0.5–2.5 hr; Adults: 2–3 hr (increased in renal impairment, decreased in patients with burns).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal